4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12

RODRÍGUEZ, MARCELO M.; FIORE, ESTEBAN; BAYO, JUAN; ATORRASAGASTI, CATALINA; GARCÍA, MARIANA; ONORATO, AGOSTINA; DOMÍNGUEZ, LUCIANA; MALVICINI, MARIANA; MAZZOLINI, GUILLERMO

MOLECULAR THERAPY (PRINT)

NATURE PUBLISHING GROUP

Año: 2018 vol. 26 p. 2738 - 2750

1525-0016

The tumor microenvironment (TME) represents a complex interplay between different cellular components, including tumor cells and cancer stem cells (CSCs), with the associated stroma; such interaction promotes tumor immune escape and sustains tumor growth. Several experimental approaches for cancer therapy are focused on TME remodeling, resulting in increased antitumor effects. We previously demonstrated that the hyaluronan synthesis inhibitor 4-methylumbelliferone (4Mu) decreases liver fibrosis and induces antitumor activity in hepatocellular carcinoma (HCC). In this work, 4Mu, in combination with an adenovirus encoding interleukin-12 genes (AdIL-12), elicited a potent antitumor effect and significantly prolonged animal survival (p < 0.05) in an orthotopic HCC model established in fibrotic livers. In assessing the presence of CSCs, we found reduced mRNA levels of CD133+, CD90+, EpCAM+, CD44+, and CD13+ CSC markers within HCC tumors (p < 0.01). Additionally, 4Mu downregulated the expression of the CSC marker CD47+ on HCC cells, promoted phagocytosis by antigen-presenting cells, and, combined with Ad-IL12, elicited a potent cytotoxic-specific T cell response. Finally, animal survival was increased when CD133low HCC cells, generated upon 4Mu treatment, were injected in a metastatic HCC model. In conclusion, the combined strategy ameliorates HCC aggressiveness by targeting CSCs and as a result of the induction of anticancer immunity. The tumor microenvironment mediates resistance to different therapeutic approaches, including immunotherapy. In this issue of Molecular Therapy, Mazzolini et al. showed that tumor remodeling using 4-methylumbelliferone (4Mu) ameliorated hepatocellular carcinoma aggressiveness by targeting cancer stem cells and increasing antitumor immune response induced by gene therapy of interleukin-12.